Clinical Practice Guideline

Evaluation and Treatment of Adult Growth Hormone Deficiency

June 01, 2011

Full Guideline: Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
JCEM June 2011
Mark E. Molitch, David R. Clemmons, Saul Malozowski, George R. Merriam, Mary Lee Vance

Objective:

The aim was to update The Endocrine Society Clinical Practice Guideline on Evaluation and Treatment of Adult Growth Hormone Deficiency (GHD) previously published in 2006.

Conclusions:

  • GHD can persist from childhood or be newly acquired.
     
  • Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood.
     
  • GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD.
     
  • The risks associated with GH treatment are low.
     
  • GH dosing regimens should be individualized.
     
  • The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual.

arrow Read the Full Guideline

Clinical Practice Guideline Mobile App
Access guideline recommendations, patient information, and clinical education modules for a range of endocrine topics plus dozens of interactive decision algorithms and other point-of-care tools.

Clinical Practice Guideline Mobile App

Download our CPG Mobile App

Access guideline recommendations, patient information, and clinical education modules for a range of endocrine topics plus dozens of interactive decision algorithms and other point-of-care tools.

Newly Designed CPG Mobile App
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.